Ionis Pharmaceuticals, Inc.
Modulators of IRF5 expression
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF5 expression, which may be useful for treating, preventing, or ameliorating a disease associated with IRF5.
Status:
Grant
Type:
Utility
Filling date:
15 Nov 2019
Issue date:
28 Dec 2021